Media coverage about Inovio Pharmaceuticals (NASDAQ:INO) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.9538039637279 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern’s rankings:
- SemaThera inks deal for China and Japan – BioPharma Dive (biopharmadive.com)
- Inovio’s China Partnership License Agreement Should Be Cheered – Seeking Alpha (seekingalpha.com)
- Breathtaking Stocks: Inovio Pharmaceuticals, Inc., (NASDAQ: INO), The Interpublic Group of Companies, Inc., (NYSE … – TNN (tradingnewsnow.com)
- Blog Exposure – Inovio Pharma Closed Collaboration Deal with ApolloBio to Develop and Commercialize VGX-3100 in Greater China (finance.yahoo.com)
- Inovio Pharmaceuticals, Inc. (INO) trend is considered bullish as stock price is 12.47% rising from 50 SMA – Analyst Recommendation (press release) (blog) (analystrecommendation.com)
INO stock opened at $4.77 on Friday. The stock has a market capitalization of $461.06, a P/E ratio of -4.42 and a beta of 2.55. Inovio Pharmaceuticals has a 52-week low of $3.76 and a 52-week high of $9.86.
A number of equities analysts have commented on the company. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada lifted their target price on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Thursday, March 15th. Maxim Group set a $8.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 15th. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. Finally, ValuEngine downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $19.07.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.